---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-004793"
form_type: "8-K"
ticker: "GCTK"
cik: "0001506983"
company_name: "Glucotrack, Inc."
filed_at: "2025-02-04T23:59:59+00:00"
generated_at: "2026-05-27T03:25:25.655526+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Glucotrack completes 1:20 reverse stock split; first human CBGM study successful with no serious adverse events

## Summary
- Effective Feb 3, 2025, every 20 pre-split shares combined into 1 share; outstanding shares reduced from ~155.5M to ~7.8M.
- First in-human CBGM study met primary endpoint: no procedure- or device-related serious adverse events from implant through 7 days post-removal.
- Six participants with diabetes mellitus; CBGM sensor lead placed intravascularly in subclavian vein for 4-day in-hospital monitoring.
- Study confirmed CBGM sensor lead function; system accuracy consistent with prior animal studies; next step is long-term clinical trials.
- Ticker GCTK unchanged; new CUSIP 45824Q705; shares trade on split-adjusted basis from Feb 4, 2025.

## SEC filing metadata
- accession: 0001493152-25-004793
- form_type: 8-K
- ticker: GCTK
- cik: 0001506983
- company_name: Glucotrack, Inc.
- filed_at: 2025-02-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.03, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1506983/000149315225004793/0001493152-25-004793-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1506983/000149315225004793/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-004793
- JSON: https://secwatch.observer/filing/0001493152-25-004793.json
- Plain text: https://secwatch.observer/filing/0001493152-25-004793.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.